|http://ghr.nlm.nih.gov/ A service of the U.S. National Library of Medicine®|
The official name of this gene is “sodium channel, voltage gated, type I alpha subunit.”
SCN1A is the gene's official symbol. The SCN1A gene is also known by other names, listed below.
The SCN1A gene belongs to a family of genes that provide instructions for making sodium channels. These channels, which transport positively charged sodium atoms (sodium ions) into cells, play a key role in a cell's ability to generate and transmit electrical signals.
The SCN1A gene provides instructions for making one part (the alpha subunit) of a sodium channel called NaV1.1. These channels are found in the brain and muscles, where they control the flow of sodium ions into cells. In the brain, NaV1.1 channels are involved in transmitting signals from one nerve cell (neuron) to another. Communication between neurons depends on chemicals called neurotransmitters, which are released from one neuron and taken up by neighboring neurons. The flow of sodium ions through NaV1.1 channels helps determine when neurotransmitters will be released.
The SCN1A gene belongs to a family of genes called SC (sodium channels).
A gene family is a group of genes that share important characteristics. Classifying individual genes into families helps researchers describe how genes are related to each other. For more information, see What are gene families? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genefamilies) in the Handbook.
At least five mutations in the SCN1A gene have been identified in people with familial hemiplegic migraine type 3 (FHM3). Each of these mutations changes a single protein building block (amino acid) in the NaV1.1 channel, which alters the channel's structure. The abnormal channels stay open longer than usual, which increases the flow of sodium ions into neurons. This increase triggers the cell to release more neurotransmitters. The resulting changes in signaling between neurons make people with FHM3 more susceptible to developing these severe headaches.
More than 150 mutations in the SCN1A gene have been associated with various seizure disorders that begin in infancy or childhood. Several of these conditions are relatively mild. These conditions include simple febrile (fever-associated) seizures, which start in infancy and usually stop by age 5, and generalized epilepsy with febrile seizures plus (GEFS+). GEFS+ involves febrile and other types of seizures that can persist beyond childhood. Other conditions cause more serious seizures that last longer and may be difficult to control. These recurrent seizures can worsen over time and lead to a decline in brain function. Severe seizure disorders caused by SCN1A mutations include severe myoclonic epilepsy of infancy (SMEI) and intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC).
The SCN1A mutations that underlie seizure disorders have a variety of effects on the function of the NaV1.1 channel. The milder disorders are caused by mutations that change single amino acids in the channel, which alter the channel's structure. More severe seizure disorders can result from several different changes in the SCN1A gene. Some mutations lead to the production of a nonfunctional version of the NaV1.1 channel or reduce the number of these channels produced in each cell. Other mutations change single amino acids in critical regions of the channel. All of these genetic changes affect the ability of NaV1.1 channels to transport sodium ions into neurons. It is unclear, however, why these genetic changes lead to such a large range of seizure disorders.
A common change (polymorphism) in the SCN1A gene has been associated with the effectiveness of certain anti-seizure medications. This polymorphism, which is written as ICS5N+5G>A, alters a single DNA building block (nucleotide) in the SCN1A gene. Studies suggest that this polymorphism is associated with the maximum safe amount (dose) of the anti-seizure drugs phenytoin and carbamazepine. These drugs treat epilepsy by blocking sodium channels (such as NaV1.1) in neurons. A dose that is too small may not control seizures effectively, while a dose that is too large may cause unwanted side effects. Right now, doctors must use a trial-and-error approach to determine the correct dose for each person. Researchers are hopeful that doctors will one day be able to use the ICS5N+5G>A polymorphism to determine the safest and most effective dose of anti-seizure medications for each individual.
Cytogenetic Location: 2q24.3
Molecular Location on chromosome 2: base pairs 165,989,159 to 166,149,271
The SCN1A gene is located on the long (q) arm of chromosome 2 at position 24.3.
More precisely, the SCN1A gene is located from base pair 165,989,159 to base pair 166,149,271 on chromosome 2.
See How do geneticists indicate the location of a gene? (http://ghr.nlm.nih.gov/handbook/howgeneswork/genelocation) in the Handbook.
You and your healthcare professional may find the following resources about SCN1A helpful.
You may also be interested in these resources, which are designed for genetics professionals and researchers.
See How are genetic conditions and genes named? (http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/naming) in the Handbook.
acids ; action potential ; amino acid ; carbamazepine ; cell ; channel ; DNA ; epilepsy ; familial ; fever ; gene ; hemiplegic ; ions ; migraine ; nerve cell ; neuron ; neurotransmitters ; nucleotide ; polymorphism ; protein ; seizure ; side effects ; sodium ; sodium channel ; subunit ; syndrome ; voltage
You may find definitions for these and many other terms in the Genetics Home Reference Glossary (/glossary).
The resources on this site should not be used as a substitute for professional medical care or advice. Users seeking information about a personal genetic disease, syndrome, or condition should consult with a qualified healthcare professional. See How can I find a genetics professional in my area? (http://ghr.nlm.nih.gov/handbook/consult/findingprofessional) in the Handbook.